April 11th 2024
Combining rintatolimod with pembrolizumab may confer a synergistic effect in patients with recurrent ovarian cancer.
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?
View More
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Community Practice Connections™: 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Expert Illustrations & Commentaries™: Exploring the Mechanistic Rationale for Targeting FGFR2 and Pan-FGFR in CCA
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
The 14th Asia-Pacific Primary Liver Cancer Expert Meeting
July 18 - 20, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Racial Disparities in Palliative Care Use Found Among Patients with Ovarian and Cervical Cancer
February 7th 2021Data published in Data in Brief described an analysis that examined palliative care use among different racial and ethnic groups with metastatic gynecologic cancers, including ovarian, cervical, and uterine cancer.
Study Finds Current Maintenance Strategies for Primary Ovarian Cancer Lack Cost-Effectiveness
January 9th 2021A study of simulated patients with primary epithelial ovarian cancer found that none of the maintenance therapy regimens evaluated were cost-effective when compared with observation following frontline response.
Phase 3 ARIEL4 Study Meets Primary End Point in Relapsed, BRCA-Mutant Ovarian Cancer
January 7th 2021The phase 3 ARIEL4 trial is evaluating rucaparib (Rubraca) versus chemotherapy in patients with platinum-sensitive, partially platinum-sensitive, and platinum-resistant relapsed ovarian cancer and a BRCA mutation who have received 2 or more prior lines of chemotherapy.
Phase 2 Trial Reports Positive Outcomes with Treatment Combination for Ovarian Cancer
November 27th 2020A phase 2 trial found that the combination of pembrolizumab with bevacizumab and oral cyclophosphamide was well tolerated and demonstrated clinical benefit and durable treatment responses in patients with recurrent ovarian cancer.
Study Finds Assisted Reproductive Technology Does Not Lead to Increased Risk of Ovarian Cancer
November 18th 2020This study found that the increased risk of ovarian cancer in women treated with assisted reproductive technology compared with the general population can likely be explained by nulliparity instead.
EU Approves Olaparib in Combination with Bevacizumab to Treat Advanced Ovarian Cancer
November 6th 2020AstraZeneca and Merck announced that the combination treatment of olaparib with bevacizumab to treat adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer was approved in the European Union.
Atezolizumab Plus Bevacizumab/Chemo Does Not Significantly Improve PFS for Ovarian Cancer
September 26th 2020The phase 3 IMagyn050/GOG 3015/ENGOT-OV39 trial indicated that the addition of atezolizumab to bevacizumab and chemotherapy failed to significantly improve progression-free survival in patients with newly diagnosed stage III/IV ovarian cancer.
ICON8 Study Finds Weekly Dose-Dense Chemo Not Superior to Standard of Care
September 22nd 2020The study found that that weekly dose-dense chemotherapy is not superior to standard 3 weekly chemotherapy for patients with epithelial ovarian cancer with regard to progression-free survival and overall survival.
5-Year Follow-up from Phase 3 SOLO-1 Continues to Show Long-Term PFS with Olaparib
September 18th 2020The phase 3 SOLO-1 trial is evaluating olaparib versus placebo as a first-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who had a complete or partial response following platinum-based chemotherapy.
Thomas Slavin, MD, FACMG, DABCC, Discusses the Use of the myChoice CDx for Ovarian Cancer
September 11th 2020New guidelines published by the American Society for Clinical Oncology (ASCO) on the use of PARP inhibitors in the management of ovarian cancer included the myChoice CDx as the sole companion diagnostic to be used in this space.